by Paul Lelieveld | Sep 18, 2023 | Meneldor News
Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics....
by Paul Lelieveld | Jun 24, 2023 | Meneldor News
Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and...
by Paul Lelieveld | Nov 9, 2022 | Meneldor News
• Christian Pangratz to become Chief Executive Officer of Atriva Therapeutics GmbH effective January 15, 2023 • Dr. Rainer Lichtenberger, co-founder and CEO, retires after a transition period as Co-CEO of at least six months • With positive POC data from RESPIRE study...
by Paul Lelieveld | Oct 19, 2022 | Meneldor News
Oslo, Norway – October 19, 2022 – Hemispherian AS (“Hemispherian” or the “Company”), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce a successful...
by Paul Lelieveld | Sep 20, 2022 | Meneldor News
Atriva Therapeutics GmbH announces high-level results from the Phase 2a RESPIRE study Results indicate a clinically relevant efficacy profile for zapnometinib, in terms of the primary endpoint, clinical severity status (CSS) at Day 15, with a favorable safety profile...
